1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Shanghai Hile Bio-Technology Co., Ltd.

Shanghai Hile Bio-Technology Co., Ltd.

603718.SS
Shanghai Hile Bio-Technology Co., Ltd.CN flagShanghai Stock Exchange
2.79
CNY
-0.15
- -
1.82BMarket Cap
Shanghai Hile Bio-Technology Co., Ltd.
603718.SS
(Shanghai Stock Exchange)

Recent

price

2.79

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.48
0.61
0.63
0.59
0.56
0.52
0.48
0.36
0.46
0.29
0.52
0.47
0.38
0.43
0.29
0.5
Revenue per Share
0.2
0.22
0.23
0.21
0.17
0.13
0.18
0.03
0.02
0.01
0.08
0.19
0.1
0.27
-0.48
0.32
Basic EPS, GAAP
0.18
0.17
0.24
0.05
0.11
-0.04
-0.08
-0.13
0.03
0.15
0.01
0.43
-0.03
0.06
0.07
-0.02
Free Cash Flow per Basic Share
0.2
0.1
0.2
0.09
0.25
0.05
0.06
0.06
0.01
- -
- -
- -
0.06
0.03
0.19
0.04
Dividend per Share
0.49
0.62
0.64
0.77
0.7
1.18
1.35
1.18
1.39
0.95
1.22
1.46
1.54
1.92
1.05
2.25
Book Value per Share
0.69
0.86
0.91
1.07
1.6
1.33
1.52
0.97
1.08
0.7
0.98
1.27
1.45
1.01
0.71
1.23
Tangible Book Value per Share
536
508
506
485
561
658
632
710
608
893
673
640
629
634
649
545
Basic Weighted Avg Shares
260
311
319
285
317
343
304
255
278
259
347
300
241
271
188
273
Sales/Revenue/Turnover
43.31
39.95
40.12
34.53
30.82
18.39
30.91
1.7
-0.92
-8.35
10.71
22.15
2.09
10.89
25.06
29.92
Operating Margin (%)
11
22
25
28
30
46
52
54
58
58
58
47
40
37
18
- -
Depreciation Expense
107
113
119
101
95
86
114
21
12
9
54
122
63
171
-311
174
Net Income, GAAP
15.06
14.65
15.01
14.68
15.7
8.91
11.04
- -
486.83
- -
20.08
15.64
10.73
12.72
- -
10.95
Effective Tax Rate (%)
41.24
36.21
37.26
35.48
30.14
24.91
37.46
8.37
4.37
3.44
15.51
40.54
26.12
63.16
-165.77
63.79
Profit Margin (%)
168
246
291
305
682
569
361
140
165
102
305
344
146
592
484
611
Working Capital
- -
- -
- -
- -
86
130
- -
- -
- -
- -
3
15
- -
14
10
13
LT Debt
406
468
501
559
963
1,005
1,075
1,025
993
962
987
1,111
1,175
1,703
896
1,742
Total Equity
- -
23.26
21.69
15.86
10.19
5.03
6.7
- -
0.96
- -
3.05
5.17
0.38
1.76
- -
4.82
Return on Invested Capital (%)
- -
37.63
35.63
27.02
22.07
13.92
13.91
- -
-2.4
- -
9.17
16
8.39
14.08
- -
12.33
Return on Capital (%)
- -
38.79
37.16
29.06
24.94
14.63
13.95
2.52
1.45
1.06
6.45
13.85
6.62
15.69
-32.81
15.78
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
4
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
14
14
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
658
656
656
Market Capitalization
2,570
3,728
4,055

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
692
678
691
Cash, Cash Equivalents & STI
517
476
516
Accounts Receivable, Net
108
125
103
Inventories
55
58
62
Total Current Liabilities
100
82
80
Payables & Accruals
- -
- -
- -
ST Debt
4
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.89%
3.69%
-47.39%
Free Cash Flow
451.07%
809.93%
22.53%
Net Income, GAAP
34.3%
94.24%
-281.93%
Sales/Revenue/Turnover
-3.43%
-3.49%
-30.69%
Total Cash Common Dividend
557.19%
1,152.96%
466.73%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
70
37
67
97
271
2025
62
48
38
- -
188
2026
47
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
- -
- -
- -
0.27
2025
0.02
- -
- -
- -
-0.48
2026
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.03
2025
- -
- -
- -
- -
0.19
2026
- -
- -
- -
- -
- -
Similar Companies
CTT Pharmaceutical Holdings, Inc. (CTTH)
ProText Mobility, Inc. (TXTM)
Nyrada Inc. (NYR.AX)
That Marketing Solution, Inc. (TSTS)
Scorpius Holdings, Inc. (SCPX)
Delota Corp. (SYDRF)
Business
Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces and sells veterinary biological products primarily for livestock and poultry in China. The company offers a broad portfolio of vaccines including swine fever live vaccines; trivalent inactivated vaccines for piglets; inactivated vaccine for streptococcus suis; inactivated avian infectious rhinitis vaccines; newcastle disease and avian influenza combined inactivated vaccines; newcastle disease, infectious bronchitis, egg drop syndrome and avian influenza quadruple inactivated vaccines; avian influenza inactivated vaccines; newcastle disease, infectious bronchitis and avian influenza triple inactivated vaccines; avian infectious bronchitis live vaccines; and avian newcastle disease and avian infectious bronchitis combined live vaccines. Founded in 1981 and headquartered in Shanghai, the company operates mainly in the domestic market with a focus on epidemic prevention for major animal diseases and maintains R&D centers recognized as Shanghai Enterprise Technology Center and Shanghai Veterinary Biologics Engineering Technology Research Center. In recent developments, Shanghai Hile Bio-Technology agreed in 2024 to acquire a 55% stake in Shaanxi Reshine Biotech Co., Ltd., a producer of oral tissue repair and regeneration materials, from Maylion Management Limited for approximately CNY 935 million in cash to expand into human biomedical applications amid growing dental implant demand; it also plans to sell its 30% stake in certain vaccine-related assets to WuXi Biologics to streamline operations and enhance liquidity. These strategic moves deepen the company's "human protection" business segment alongside its core "animal insurance" veterinary offerings.